To Participate in the TIGeR-PaC study, Candidate Patients Must Meet the Following Minimum Criteria:
- Diagnosis of locally advanced pancreatic cancer
- Not a candidate for surgery
- No prior therapy for pancreatic cancer or no more than 3 treatments with gemcitabine-Abraxane
Note: Before a patient is enrolled in the study, the patient must be evaluated by one of the physicians in the TIGeR-PaC study. The physician will review the study in detail with the patient to ensure that the study is well-suited for the patient.